Tango Therapeutics (NASDAQ: TNGX) reported a fourth‑quarter 2025 loss of $0.29 per share, beating the consensus estimate of $0.32 per share by $0.03, a 9.4% improvement. The company’s net loss narrowed to $101.6 million from $130.3 million in 2024, while full‑year collaboration revenue rose to $62.4 million from $30.0 million, reflecting a 107% year‑over‑year increase. The Q4 loss of $38.7 million was also lower than the $30.8 million loss reported in Q4 2024, underscoring a steady decline in operating expenses relative to revenue growth.
The company’s cash balance stood at $343.1 million as of December 31 2025, providing a runway that extends into 2028. Management reiterated its confidence in meeting 2026 milestones, including the launch of the pivotal vopimetostat study in second‑line pancreatic cancer and the pursuit of additional collaboration agreements. The company’s focus on precision oncology for MTAP‑deleted tumors remains unchanged, with vopimetostat positioned as a potential turning point for multiple difficult‑to‑treat cancers.
Malte Peters, M.D., President and CEO, said, "We enter 2026 with a clear focus on execution, building on the significant progress achieved across our development portfolio in 2025." In November 2025, former President and CEO Barbara Weber, M.D., noted, "We are wrapping up 2025 with significant momentum, supported by our recent disclosure of vopimetostat clinical data, supporting the potential of this compound to be a turning point for treatment of multiple difficult‑to‑treat MTAP‑del cancers, beginning with pancreatic cancer."
Investors responded favorably to the earnings release, citing the company’s improved loss profile, the substantial growth in collaboration revenue, and the strong cash runway as key drivers. The announcement of a new collaboration with Erasca for a vopimetostat combination study further bolstered confidence in Tango’s pipeline and partnership strategy.
The market reaction was also influenced by the company’s reaffirmation of its 2026 execution plan and the continued expansion of its collaboration portfolio, which includes agreements with Revolution Medicines and the newly announced partnership with Erasca. These developments reinforce Tango’s strategic positioning in the precision oncology space and support its long‑term growth prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.